Providing an overview on where the healthcare reform debate is headed, Andrew Slavitt, former head of CMS, refined the discussion to highlight the potential for biosimilars to influence the rising costs of drug products.
A much-awaited talk at the 2017 AAM Biosimilars Council Conference, held in Washington DC, was by Andrew Slavitt, senior advisor, Bipartisan Policy Center and former acting administrator, CMS. Providing an overview on where the healthcare reform debate is headed, Slavitt refined the discussion to focus on drug cost and indicated the potential for biosimilars to influence the rising costs of drug products.
Acknowledging the 2 press conferences that were being held by senators on the same day, where the lawmakers were to unveil new healthcare reform proposals, Slavitt predicted, “To my mind, every 10 years or so, we are due for another healthcare debate in this country. If you go back as far as Medicare and Medicaid, Medicare Advantage, Medicare Part D, Obamacare, and then of course the current battle…this could be another battle of sorts in 10 years.”
Slavitt went on to take stock of what the Affordable Care Act (ACA) accomplished, including reducing the uninsured rate, investing in healthcare cost and quality of care, and ensuring healthcare insurance for all American citizens, independent of their health or financial status. He acknowledged that the ACA did not get it all right in terms of fixing problems, including affordability of healthcare, which encompasses the absence of competition in the insurance marketplace in several states.
Slavitt said that every American should have access to affordable care, preventing healthcare-associated bankruptcy. Ensuring this can be sustained and achieved by 2020, the current focus should be:
The healthcare challenge in our country, Slavitt explained, “is not the 50-year old jogger with mobile monitoring devices. The challenge is the woman who lives 2 bus stops away from a dialysis center and who may be in renal failure if she misses one of the connections.” Social determinants of health, which are outside of healthcare control, need to be addressed, he said, adding that we need to move innovation away from gadgets like Fitbit and refocus on some of these social issues.
Moving the discussion toward drug costs, he said that this problem is not forthcoming; it’s a problem we face today. “We cannot talk about affordability of healthcare in exchanges without getting into the underlying root cause.” Narrating his experiences of heading CMS, he said that, when he would talk to heads of healthcare systems or the pharmaceutical industry about keeping down or regulating the cost of care, the feedback would be:
“This is where biosimilars come in,” Slavitt said. He made note of changes being made by FDA Commissioner Scott Gottlieb, MD, to improve competition in the marketplace.
He reiterated his faith in competition, innovation, value-based ideas, and the ability for CMS to negotiate drug prices. Going back to the single-payer proposition, which is being presented by Senator Bernie Sanders (I-Vermont), he said there are provisions in his bill and opportunities that are relative to generic drugs and biosimilars.
He closed by saying that the affordability questions will be ever-present, and that biosimilars and generic drugs may have a significant role to play in being part of the solution. “Being there and part of the solution while key legislations are being drafted or as people are focused on policy issues is a great place to be.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.